2006 Releases

Roswell Park Awarded $2.4 Million to Study Use of Antioxidants During Chemotherapy: Nov-20-2006 — Christine Ambrosone, PhD, Chair of Epidemiology and Cancer Prevention at RPCI has been awarded a four-year, $2.4 million grant from the National Cancer Institute to study the role antioxidant supplements play during chemotherapy.
Research May Lead to Test to Predict Breast Cancer Risk: Nov-08-2006 — Research in the Department of Cancer Genetics at RPCI led by Nicoletta Sacchi, PhD, provides the basis for a sensitive molecular test that could predict breast cancer risk and prevent the development of the disease.
Roswell Park Researchers Identify Potential Lung Cancer Biomarker: Oct-26-2006 — Surveillance for lung cancer may have taken a step forward with the identification of a potential biomarker for the disease, in research led by Gregory Loewen, DO, Department of Medicine, RPCI.
Technology Transfer at RPCI: Oct-11-2006 — Roswell Park is expanding its research focus to develop a full Technology Transfer Department at the Institute. Dr. Richard Matner joined the team to expand the possibilities...
Roswell Park Awarded Over $1 Million for Landmark Study of Weight Gain and Breast Cancer Recurrence: Sep-27-2006 — Can hormonal changes and genetic variants in breast cancer patients contribute to a weight gain that increases the chance of cancer recurrence?
Susan G. Komen Breast Cancer Foundation Awards $883,986 for Breakthrough Breast Cancer Research: Sep-22-2006 — Awarded to researchers at Roswell Park studying innovative approaches to treating and preventing breast cancer.
Roswell Park Researcher Awarded $169,000 to Develop Vaccine: Sep-01-2006 — Brahm Segal, MD, Department of Medicine, RPCI, was awarded a $169,000 grant from the Chronic Granulomatous Disorder Research Trust to develop a vaccine for the prevention and treatment of aspergillus infections.
RPCI Researchers Evaluate World-Wide Effort to Implement Tobacco Control Policies: Aug-08-2006 — Scientific evidence can be used to direct and support tobacco control policies around the world, according to the journal Tobacco Control. K. Michael Cummings, PhD, Health Behavior at RPCI is one of the lead scientists on the International Tobacco Control Policy Evaluation Project.
Roswell Park Research Aids Development of Myeloma Drug: Jul-10-2006 — Roswell Park Cancer Institute (RPCI) researchers played a leading role in clinical studies which led to U.S. Food and Drug Administration (FDA) approval of a new treatment for patients diagnosed with multiple myeloma - the second most common blood cancer.
Mechanisms of Resistance to Rituximab Coming into View: Jun-06-2006 — The fog may be lifting as to the mechanisms of treatment resistance due to a promising therapy for patients with lymphoma, according to a study by RPCI researchers.
New Research Helps Raze Road Blocks to Effective Chemotherapy for Rare Leukemia: Jun-05-2006 — Two avenues to overcome resistance to chemotherapy in a rare blood cancer have been discovered by a research team at RPCI, who will present them at the annual meeting of the American Society of Clinical Oncology, June 2-6, in Atlanta, GA.
Information Technology Streamlines Breast Cancer Care: Jun-05-2006 — Electronic linking of medical records between providers and health insurance payers can facilitate appropriate follow-up care for women whose mammograms show abnormal findings, according to a research team at RPCI.
Leukemia Patients Respond to Novel Oral Cancer Treatment: Jun-04-2006 — Patients treated with lenalidomide for relapsed chronic lymphocytic leukemia (CLL) have experienced a major response to therapy, according to a study conducted by Asher Chanan-Khan, MD, RPCI.
“Young Investigator” Honored with Prestigious National Research Grant: Jun-03-2006 — Naoyuki G. Saito, MD, PhD, Departments of Radiation Medicine and Pharmacology & Therapeutics at RPCI will be presented with a “Young Investigator Award” by ASCO at its annual meeting.
Pancreatic Cancer Patients Live Longer With Novel Chemotherapy Combination: Jun-03-2006 — Combining a monoclonal antibody that inhibits the formation of new blood vessels with standard chemotherapy extends survival and improves quality of life for patients with advanced pancreatic cancer.
Past Secretary/Treasurer of ASCO to Lead Prostate Cancer Discussion at Annual Meeting: Jun-03-2006 — Donald L. Trump, MD, Senior Vice President, RPCI, will lead a scientific discussion titled “Novel Targets in Prostate Cancer” at the 2006 annual meeting of ASCO.
Pancreatic Cancer Investigation Offers New Insight into Deadly Disease: Jun-03-2006 — Novel findings regarding biomarkers which correlate with poor outcomes after surgery for pancreatic cancer are presented by RPCI researchers at the 2006 annual meeting of the American Society of Clinical Oncology, June 2-6, Atlanta, GA.
Treatment Stabilizes Patients with Advanced Colorectal Cancer: Jun-03-2006 — A new anti-cancer agent may have a role in the treatment of metastatic colorectal cancer, according to a study by RPCI researchers led by Marwan Fakih, MD, Department of Medicine.
Quality of Cancer Care Focus of Scientific Symposium Directed by RPCI Faculty Member: Jun-03-2006 — Stephen B. Edge, MD, Chair of Breast and Soft Tissue Surgery at RPCI will lead a clinical scientific symposium, titled “Quality Measurement: How Do I Do It? How Will It Affect My Practice and My Patients?” at ASCO, June 2-6, Atlanta.
UB's Center of Excellence and RPCI Center for Genetics and Pharmacology Celebrate Grand Opening: Jun-03-2006 — Creation of a life-sciences industry and economy for Buffalo Niagara takes an historic step forward with the grand opening of UB's New York State Center of Excellence in Bioinformatics and Life Science and the RPCI Center for Genetics and Pharmacology.
World-Class Buffalo Life Sciences Complex Designed To Break Down R&D Barriers: Jun-02-2006 — New complex is expected to attract outstanding research talent, facilitate unprecedented collaboration between public academic research, private for-profit science, and medical products developers.
Silver and Gold Nanocomposites Promising as Cell Biomarkers: May-11-2006 — Silver and gold are precious metals that may be the key ingredients of nanocomposites designed to measure the actual amounts of drugs being absorbed by cancer cells, according the results of a new RPCI study.
Technological Advances Promise to Improve Medication Safety: May-02-2006 — The Failure Mode Effects Analysis is an effective strategy for identifying and adopting safe medication practices and improving medication safety, according to a paper authored by Ellen Zupa of RPCI.
Design Improvements in Nanodevices Mean More Precise, More Effective Treatment Targeting: Apr-07-2006 — Changing the size and surface charge of nanodevices significantly alters the way the nanodevices are taken up by organs and tissues in the body. This should allow for better targeting of treatments...
Kunle Odunsi, MD, to Discuss the Immune System and Cancer: Apr-07-2006 — Kunle Odunsi, MD, PhD, Department of Gynecologic Oncology at RPCI, will speak at the Education Session, “Immunology 101: Basic Concepts and Applications to Cancer Epidemiology” at AACR.
McCann to Discuss Research About Dietary Lignan Intake: Apr-07-2006 — Susan McCann, PhD, to Discuss Findings of Research in the Association of Dietary Lignan Intake with ER Negative and ER Positive Breast Cancer Risk.
Scientists Zero in on New Molecular Target for Colorectal Cancer: Apr-07-2006 — A novel characteristic on the cell’s surface could hold the key to more effective therapies for patients with advanced colorectal cancer, according to scientists from the Department of Surgical Oncology, RPCI.
Use of Vitamin D for Suppressing Cancer Growth Can Be Enhanced, Study Shows: Apr-07-2006 — A new way to help the body absorb and retain the most active form of vitamin D (calcitriol) holds promise for cancer patients.
RPCI Researchers Say Higher Intakes of Tea and Milk May Reduce Risk of AML in Women But...: Apr-07-2006 — A diet with higher intakes of milk and tea may lower women’s risk of developing acute myeloid leukemia (AML), according to scientists from the laboratory of Susan McCann, PhD, Division of Cancer Prevention & Population Sciences, RPCI.
New Drug Combination May Enhance Effectiveness of Colorectal Cancer Treatments: Apr-07-2006 — Take the “gold standard” chemotherapy drug regimen for colorectal cancer, add a new investigational drug to the mix and you may offer a more effective formula for enhancing the treatment’s ability to kill tumor cells in this disease...
New Drug May Offer Double Benefits for Patients with Non-Hodgkin Lymphoma: Apr-07-2006 — A new drug may boost the effectiveness of a widely used treatment for patients with Non-Hodgkin Lymphoma (NHL), while simultaneously overcoming drug resistance in those patients.
RPCI Researchers “Mine” the Potential of Selenium Trace Mineral; May Prevent, Treat Prostate Cancer: Apr-07-2006 — Selenium, a trace mineral found naturally in plant foods, meats and seafood, may be effective for both treating and preventing prostate cancer, according to scientists from the departments of Medicine and Pharmacology & Therapeutics, RPCI.
New Insight Into Risk Factors for Graft-Versus-Host Disease May Lead to Better BMT Outcomes: Apr-07-2006 — New understanding of changes in risk factors for acute graft-versus-host disease may help identify high-risk patients and lead to greater success in blood and marrow transplantation (BMT), according to RPCI scientists.
Roswell Park Researchers ID Possible New Approaches To Combat Colon Cancer: Apr-07-2006 — Innovative new gene-based approaches for combating colon cancer have been identified by scientists from the laboratory of Michael Brattain, PhD, Senior Vice President for Basic Research and Chairman of the Department of Pharmacology & Therapeutics, RPCI.
Roswell Park Scientists Discover Gene That May Halt Cancer Spread; Makes Cover of Molecular Research: Apr-03-2006 — Labeled SSeCKS/Gravin/AKAP12, the gene was discovered by Irwin Gelman, PhD, vice chair of the Department of Cancer Genetics at RPCI, and colleagues in his lab, and featured on the cover of the March 2006 issue of Molecular Cancer Research.
Roswell Park Recruiting Patients for Photodynamic Therapy Study: Jan-10-2006 — Roswell Park Cancer Institute is recruiting patients who have been diagnosed with superficial cancerous and precancerous lesions of the mouth to volunteer for a research study to evaluate the effectiveness of photodynamic therapy (PDT) with Photofrin®.